Sarah N. Boers, MD Department/Faculty: Julius Center, department of Medical Humanities, UMC Utrecht University: UMC Utrecht, Utrecht University Email address: [email protected]Bio Sarah Boers (Rotterdam, 1988) studied medicine at the University Medical Center in Utrecht and obtained her master's degree in 2014. During her research internship in medical ethics she collaborated with prof. dr. Annelien Bredenoord on a project concerning the disclosure of genetic information to family after a patient's death. In October 2014 she started as a PhD candidate in medical ethics under supervision of prof. dr. Hans van Delden and prof. dr. Annelien Bredenoord. In her PhD project she focuses on the "Ethics of Organoid Technology". Organoid technology is a novel stem cell technology with a great promise for personalized medicine, drug development, and regenerative medicine. In this project her main emphasis is on the ethical challenges that surround biobanking: the donation, storage of use of mini- organs for scientific, clinical, and commercial aims. As of June 2016 she combines finishing her PhD with a ZonMw funded project, entitled 'The ethics of first-in-human organoid transplantation'. In this project she shifts her focus to the translation of organoids from bench to bedside. How to design an ethically sound first-in-human organoid trial, together with a multidisciplinary team, while taking into account the needs and preferences of patients? In addition, she is involved in teaching several courses at the faculty of medicine and the Graduate School of Life Sciences. Key Publications Organoid technology: Identifying the ethics. Sarah N. Boers, Johannes J.M. van Delden, Hans Clevers, Annelien Bredenoord. EMBO Reports, 2016 (in press) Broad consent is consent for governance Sarah N. Boers, Johannes J.M. van Delden, Annelien L. Bredenoord American Journal of Bioethics, 2015; 15; 53-55 Postmortem disclosure of genetic information to family members: active or passive? Sarah N. Boers, Johannes J.M. van Delden, Nine V. Knoers, Annelien L. Bredenoord Trends in Molecular Medicine, 2015; 21; 148-153
17
Embed
Sarah N. Boers, MDSarah N. Boers, MD Department/Faculty : Julius Center, department of Medical Humanities, UMC Utrecht University : UMC Utrecht, Utrecht University Email address :
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Sarah N. Boers, MD Department/Faculty: Julius Center, department of Medical Humanities, UMC Utrecht University: UMC Utrecht, Utrecht University Email address: [email protected]
Bio Sarah Boers (Rotterdam, 1988) studied medicine at the University Medical Center in Utrecht and obtained her master's degree in 2014. During her research internship in medical ethics she collaborated with prof. dr. Annelien Bredenoord on a project concerning the disclosure of genetic information to family after a patient's death. In October 2014 she started as a PhD candidate in medical ethics under supervision of prof. dr. Hans van Delden and prof. dr. Annelien Bredenoord. In her PhD project she focuses on the "Ethics of Organoid Technology". Organoid technology is a novel stem cell technology with a great promise for personalized medicine, drug development, and regenerative medicine. In this project her main emphasis is on the ethical challenges that surround biobanking: the donation, storage of use of mini-organs for scientific, clinical, and commercial aims.
As of June 2016 she combines finishing her PhD with a ZonMw funded project, entitled 'The ethics of first-in-human organoid transplantation'. In this project she shifts her focus to the translation of organoids from bench to bedside. How to design an ethically sound first-in-human organoid trial, together with a multidisciplinary team, while taking into account the needs and preferences of patients?
In addition, she is involved in teaching several courses at the faculty of medicine and the Graduate School of Life Sciences.
Key Publications
Organoid technology: Identifying the ethics. Sarah N. Boers, Johannes J.M. van
Delden, Hans Clevers, Annelien Bredenoord. EMBO Reports, 2016 (in press)
Broad consent is consent for governance
Sarah N. Boers, Johannes J.M. van Delden, Annelien L. Bredenoord American
Journal of Bioethics, 2015; 15; 53-55
Postmortem disclosure of genetic information to family members: active or
passive?
Sarah N. Boers, Johannes J.M. van Delden, Nine V. Knoers, Annelien L.
Bredenoord Trends in Molecular Medicine, 2015; 21; 148-153
Bio Dr. Joost O. Fledderus is currently working in a dual function as the Director of Administration at the UMC Utrecht Regenerative Medicine Center and as assistant professor at the Department of Nephrology and Hypertension of the UMC Utrecht. After obtaining his master’s degree in Biology at Utrecht University, he did his PhD at the Academic Medical Center (AMC) of the University of Amsterdam, studying signal transduction and whole genome gene expression in endothelial cells, smooth muscle cells and macrophages in the healthy and atherosclerotic vessel wall. In 2008 he was appointed as a postdoctoral fellow for the cardiovascular nucleus within the Regenerative Medicine strategic programme of the UMC Utrecht. In 2010, he received a pilot grant from the Dutch Diabetes Fund for a study on molecular mechanisms impairing the Nrf2-Keap1 pathway in the diabetic vascular wall. From 2011 he is working as a postdoc in the Department of Nephrology and Hypertension, supervising PhD students with projects in heart valve and blood vessel tissue engineering and autologous stem cell therapy for peripheral vascular disease and systemic sclerosis. In addition, he has a supportive role with the management team of the UMC Utrecht strategic research program Regenerative Medicine & Stem Cells (RM&SC), teaches in various courses at bachelor/master/PhD level, and is the course coordinator of the course “Introduction to RM&T” within the UU master’s programme Regenerative Medicine and Technology. From 2013-2015, he was project leader for the transition of RM&SC research labs to the UMC Utrecht Regenerative Medicine Center in the new laboratory building of the Hubrecht Institute and coordinated the move in late 2015.
Department Orthopaedics Biofabrication Facility Regenerative Medicine Center Utrecht The Netherlands Email: [email protected]
Bio Dr. Riccardo Levato is a postdoctoral researcher in Biofabrication and Regenerative Medicine at the Department of Orthopaedics, University Medical Center Utrecht (UMCU) and at the Regenerative Medicine Center Utrecht. His main research focus are in the design of cell-instructive biomaterials to tune stem cell behavior and differentiation. At UMCU, he focuses on the development of novel Biofabrication strategies to treat cartilage and osteochondral defects. Dr. Levato is an experienced researched and worked in several research groups across Europe: 3Bs, University of Minho, (Portugal); BioMatLab, Technical University of Milan (Italy), Institute for Bioengineering of Catalonia (Spain), in the field of Tissue Engineering and Regenerative Medicine. Dr. Levato holds a cum laude PhD in Bioengineering (awarded by the Technical University of Catalonia, Spain), and for his doctoral research he was conferred the 2015 Julia Polak award by the European Society for Biomaterials. For his research on Biofabrication and bioprinting he has been awarded the 2016 Wake Forest Institute for Regenerative Medicine Young Scientist Award.